WCLC 2025 - Posters & ePosters-EP.12.55 Aumolertinib Combined With Metronomic Oral Vinorelbine in Advanced EGFR-Mutant NSCLC

Pdf Summary

This study investigates the efficacy and safety of combining aumolertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), with metronomic oral vinorelbine chemotherapy in advanced non-small cell lung cancer (NSCLC) patients harboring EGFR mutations. While third-generation EGFR-TKI monotherapy is the standard first-line treatment for such patients, progression-free survival (PFS) of around 20 months remains suboptimal. Previous studies (e.g., FLAURA2) demonstrated improved PFS with EGFR-TKI plus intravenous chemotherapy, but intravenous chemotherapy is associated with inconvenience, severe adverse effects, and repeated hospital visits. Oral metronomic chemotherapy offers a potential solution.<br /><br />In this ongoing single-arm prospective study, 165 untreated EGFR-mutant advanced NSCLC patients are planned for enrollment. They receive daily aumolertinib (110 mg) combined with metronomic oral vinorelbine (40 mg thrice weekly in a 3-weeks-on/1-week-off cycle). The primary endpoint is PFS, with secondary endpoints including overall response rate (ORR), disease control rate (DCR), duration of response (DoR), and safety.<br /><br />Preliminary results from 11 patients (median age 61; all adenocarcinoma) show promising efficacy: 10 achieved partial response (PR), one achieved stable disease (SD), resulting in an ORR of 90.9% and DCR of 100%. Most patients had ECOG performance status ≥1. Importantly, no grade 3 adverse events were observed, indicating good tolerability.<br /><br />In conclusion, the combination of aumolertinib with metronomic oral vinorelbine demonstrates high response rates and favorable safety in EGFR-mutant advanced NSCLC. Further enrollment and analysis are ongoing to confirm these encouraging findings, potentially offering a more convenient and effective therapy alternative to intravenous chemotherapy combinations.

Asset Subtitle

ZhenTian Liu

Meta Tag

Speaker ZhenTian Liu

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

Aumolertinib

Metronomic oral vinorelbine

EGFR-mutant non-small cell lung cancer

Third-generation EGFR-TKI

Progression-free survival

Advanced NSCLC treatment

Partial response rate

Disease control rate

Safety and tolerability

Oral chemotherapy